OTC:BIXT
BIOXYTRAN, INC
A biotech firm developing anti-inflammatory therapeutics for metabolic diseases, currently in a cash-burn phase with significant R&D investments.
Key Metrics
Investment Thesis
Bull Case
The company possesses a unique proprietary platform for treating chronic inflammation with a favorable safety profile, and recent financing of $63 million extends its runway to pursue clinical milestones. If any assets reach late-stage development or licensing deals are struck, the current asset base of $5.1 million provides immediate liquidity.
Bear Case
With zero revenue reported across five years and a cumulative net loss exceeding $9 million since 2022, the company faces imminent financial distress without successful fundraising or commercialization. The significant retained earnings deficit of $18.9 million and negative shareholders' equity of $1.8 million indicate that current operations are not self-sustaining.
About BIOXYTRAN, INC
BIOXYTRAN, INC. (BIXT) is a biotechnology company focused on developing novel therapeutics for chronic inflammatory diseases, primarily targeting metabolic disorders in the US market. The company utilizes proprietary platforms to create small molecule drugs aimed at reducing systemic inflammation without affecting heart rate or blood pressure. Key revenue streams currently rely on research and development expenses, with no reported operating revenue from product sales.
Analysis
Management Discussion
The company reported a net loss of $2.4 million in the latest period, with operating expenses totaling $2.2 million driven by general and administrative costs of $1.2 million and research and development expenditures of approximately $0.1 million. Despite receiving $63 million from financing activities to offset cash outflows, the company's net change in cash was negative $20.9 million, reflecting continued heavy investment in its pipeline.
Industry Overview
The biotechnology sector for chronic inflammatory diseases is highly competitive, dominated by large pharma giants with established assets, making it difficult for small-cap companies to secure market share without substantial capital. Success in this space requires navigating complex regulatory pathways and securing partnerships to mitigate the high costs of clinical trials.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $2.1M | $3.8M | $2.2M |
| Operating Income | $-2.1M | $-3.8M | $-2.2M |
| R&D | $977.8K | $1.1M | $112.3K |
| G&A | $933.7K | $2.5M | $1.2M |
| Stock-Based Comp | $178.4K | $197.6K | $634.0K |
| Amortization | $3.6K | $8.3K | $8.0K |
| Other OpEx | $222.6K | $207.6K | $943.2K |
| Non-Operating Income | $-523.2K | $-550.1K | $-156.9K |
| Pre-Tax Income | $-2.7M | $-4.4M | $-2.4M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-2.7M | $-4.4M | $-2.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-2.7M | $-4.4M | $-2.4M |
| Minority Interest | $-193.4K | $-90.3K | $-13.3K |
| Net to Common | $-2.5M | $-4.3M | $-2.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $295.4K | $26.1K | $5.2K |
| Long-Term Assets | $75.5K | $111.6K | $133.5K |
| Total Assets | $370.9K | $137.6K | $138.7K |
| Current Liabilities | $3.7M | $3.2M | $1.9M |
| Long-Term Liabilities | $0 | $0 | $0 |
| Total Liabilities | $3.7M | $3.2M | $1.9M |
| Shareholders' Equity | $-3.3M | $-3.1M | $-1.8M |
| Paid-In Capital | $8.4M | $12.9M | $17.0M |
| Retained Earnings | $-11.2M | $-15.5M | $-18.9M |
| Total L&E | $370.9K | $137.6K | $138.7K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-2.7M | $-4.4M | $-2.4M |
| Non-Cash Adjustments | $726.6K | $3.9M | $2.1M |
| Working Capital Changes | $125.1K | $-265.0K | $231.9K |
| Cash from Operations | $-1.8M | $-775.4K | $-55.7K |
| Cash from Investing | $-32.2K | $-44.3K | $-28.2K |
| Cash from Financing | $2.1M | $550.4K | $63.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $223.0K | $-269.3K | $-20.9K |
| Beginning Cash | $72.4K | $295.4K | $26.1K |
| Ending Cash | $295.4K | $26.1K | $5.2K |
Frequently Asked Questions
How does BIOXYTRAN, INC make money?
Proprietary Drug Discovery Platform, Chronic Inflammatory Disease Therapeutics, Small Molecule Development Programs
What are the main risks for BIXT?
Complete lack of revenue generation leading to significant cash burn and reliance on external financing, substantial accumulated retained earnings deficit indicating long-term solvency concerns, potential dilution from equity raises given negative operating cash flow, and high regulatory uncertainty typical for early-stage biotech firms.
What is BIXT's competitive advantage?
Proprietary small molecule technology that modulates inflammation without cardiac side effects, specialized focus on metabolic disease markets, and a pipeline of late-stage clinical candidates.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.